Mobia Medical, Inc.
Mobia Medical develops neurostimulation devices for stroke rehabilitation and other chronic neurological conditions. Its Vivistim System is an implantable device intended to support recovery of upper-limb movement after stroke by pairing vagus nerve stimulation with therapy. The company also develops its paired stimulation platform for conditions such as tinnitus and provides information and resources to healthcare professionals, patients, and caregivers. Mobia Medical is based in Austin, Texas.
No SEC Form 4 filings for $MOBI in the last 30 days.
See all $MOBI insider activity →Mobia Medical (MOBI) reported Q3 GAAP EPS of -$0.52 and revenue of $15.6M, up 73% Y/Y. The company raised its full-year 2026 revenue guidance to $57M-$57.5M from $54M-$56M, with $160.7M in cash as of September 30, 2026.
Mobia Medical (MOBI) reported Q3 earnings with a net loss of $17.3M ($0.52 per share), improved from last year. Gross margin rose to 83.2%. Operating expenses increased to $31.5M due to higher personnel costs. The company cited positive impacts from revised stroke recovery guidelines and expects to publish clinical evidence in 2027.
Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mobia Medical Reports Third Quarter 2026 Financial Results Delivers revenue growth of 73% in the third quarter and raises full year 2026 revenue guidance Austin, Texas, November 5, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning MOBI (Mobia Medical, Inc.). Coverage has skewed bullish: 4 bullish, 2 neutral, and 0 bearish.
Recent MOBI coverage spans earnings, insider activity and market movers.
Guidance raise suggests improving sales momentum, likely supporting the stock.
Earnings show improved margins but larger net loss; market may view mixed signals.
Raised guidance and strong top‑line growth suggest upside potential.
Analyst upgrade with a high price target may drive buying interest.
Small insider purchase signals confidence but limited market impact due to modest size.
AlphAI scores every news story that mentions MOBI with an AI model for sentiment and relevance, and aggregates insider trades from Mobia Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Mobia Medical (MOBI) reported Q3 GAAP EPS of -$0.52 and revenue of $15.6M, up 73% Y/Y. The company raised its full-year 2026 revenue guidance to $57M-$57.5M from $54M-$56M, with $160.7M in cash as of September 30, 2026.
Mobia Medical (MOBI) reported Q3 earnings with a net loss of $17.3M ($0.52 per share), improved from last year. Gross margin rose to 83.2%. Operating expenses increased to $31.5M due to higher personnel costs. The company cited positive impacts from revised stroke recovery guidelines and expects to publish clinical evidence in 2027.
Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mobia Medical Reports Third Quarter 2026 Financial Results Delivers revenue growth of 73% in the third quarter and raises full year 2026 revenue guidance Austin, Texas, November 5, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke
BTIG reiterated a Buy rating on Mobia Medical with a $19 price target, suggesting 115.7% upside from the Oct 19 close of $8.81. The firm cited improved reimbursement dynamics and strong clinical outcomes for the Vivistim System as key drivers for potential revenue growth and adoption.
Leavitt Chase C. (SEE REMARKS) purchased 2,000 shares of Mobia Medical, Inc. (MOBI) at $10.30 on 2026-09-11.
Mobia Medical (MOBI) announced that its Vivistim Paired VNS System, the only FDA-approved device for this treatment, was included in the 2026 AHA stroke recovery guidelines. The guidelines recognize paired VNS as an option to improve upper-limb function in chronic stroke survivors. MOBI's stock is up 7.17% in pre-market trading at $11.36.
Mobia Medical Inc (MOBI) shares rose 7.2% premarket after the American Heart Association included its paired vagus nerve stimulation in 2026 stroke rehabilitation guidelines. The Vivistim Paired VNS System is the only FDA-approved system for this treatment, which may improve upper-limb function. Stroke is a leading cause of long-term disability in the U.S.
Tansey Casey M purchased 16,441 shares of Mobia Medical, Inc. (MOBI) at $12.07 ($0.20M total) on 2026-08-18.
Mobia Medical (MOBI) reported Q2 2026 revenue of $13.5M, up 102% YoY, driven by Vivistim system adoption. Full-year guidance set at $54M-$56M. Net loss was $21M, with cash reserves of $177.1M post-IPO. Management plans to expand active territories and target 1,500 U.S. stroke centers.
Tansey Casey M purchased 68,559 shares of Mobia Medical, Inc. (MOBI) at an average of $11.63 ($11.51–$12.53, $0.80M total) across 4 trades over 2026-08-13 to 2026-08-17.
